miRagen Therapeutics

99 articles with miRagen Therapeutics

• 

  BioSpace Movers & Shakers, Sept. 18

  9/18/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• miRagen Announces Leadership Transition and Review of Strategic Alternatives 

  9/14/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that its Board of Directors has appointed Lee Rauch,

• miRagen Announces Results of Meeting With FDA Regarding the Design of Pivotal Trial for Cobomarsen in ATLL

  8/20/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that the company held a Type C meeting with the FDA Office of  Oncologic Diseases on August 11, 2020 to discuss miRagen’s future clinical development plans for cobomarsen for the potential treatment of Adult T-Cell Leukemia/Lymphom

• miRagen Reports Second Quarter 2020 Financial Results and Provides Business Updates

  8/5/2020

  miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary RNA-targeted therapies with a specific focus on microRNAs, reported financial results for the second quarter ended June 30, 2020 and provided business updates.

• miRagen to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

  8/4/2020

  BOULDER, Colo., Aug. 04, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 1:10 p.m. ET. A live webcast of the event will be available on the investors page of the m

• miRagen, Investigators from Goethe University and University Hospital Frankfurt and Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data in Nucleic Acid Therapeutics

  7/28/2020

  Goethe University, University Hospital Frankfurt and miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that preliminary results from a Phase 1 trial detailing the pharmacodynamic activity of MRG-110 has been published in the peer-reviewed journal Nucleic Acid Therapeutics . “We are pleased to have the

• Cobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell Lymphoma

  7/23/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the Food & Drug Administration (FDA) has granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma.

• miRagen to Report Second Quarter 2020 Financial Results on August 5, 2020

  7/22/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it will report its second quarter 2020 financial results after the financial markets close on Wednesday August 5, 2020.   The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Wednesday August 5, 2020. To access the call, please d

• miRagen Regains Compliance With Nasdaq Listing Requirements

  7/2/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that on July 1, 2020 it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC

• miRagen Announces Encouraging Preclinical Safety and Efficacy Data for its Next-generation miR-29 Replacement Product Candidate Intended for the Treatment of Idiopathic Pulmonary Fibrosis

  6/22/2020

  miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced preclinical safety and efficacy data for MRG-229, a next-generation miR-29 mimic intended for systemic administration and targeted delivery, in Idiopathic Pulmonary Fibrosis‎.

• miRagen Strengthens Leadership Team with Appointment of Lee Rauch as Chief Operating Officer

  6/18/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the appointment of Lee Rauch as Chief Operating Officer, effective immediately.

• miRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rd

  6/16/2020

  miRagen to announce encouraging new preclinical safety and efficacy data for MRG-229 in IPF on June 22nd; and provide an update on the development program during the KOL call

• miRagen to Present at the Jefferies 2020 Virtual Global Healthcare Conference

  5/26/2020

  miRagen Therapeutics, Inc. announced that William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen, will present at the Jefferies Virtual Global Healthcare Conference on Tuesday, June 2, 2020 at 4:00 p.m. ET.

• miRagen Reports First Quarter 2020 Financial Results and Provides Corporate Update

  5/7/2020

  New ATLL data presented in the first quarter; Company plans to request a meeting with the FDA on a regulatory pathway for cobomarsen in ATLL during Q2 2020

• miRagen Therapeutics to Report First Quarter 2020 Financial Results On May 7, 2020

  4/23/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it will report its first quarter 2020 financial results after the financial markets close on Thursday, May 7, 2020.   The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Thursday, May 7, 2020. To access the call, please dial 87

• miRagen Reports Fourth Quarter and Full Year 2019 Financial Results

  3/11/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), today reported operating highlights and financial results for the quarter and full-year ended December 31, 2019 and provided an outlook for 2020.

• miRagen Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 11, 2020

  2/20/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it will report its fourth quarter and full year 2019 financial results after the financial markets close on Wednesday, March 11, 2020.  

• miRagen Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants to Purchase Common Stock

  2/7/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and warrants to purchase up to an aggregate of 7,500,000 shares of its common stock.

• miRagen Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock

  2/6/2020

  miRagen Therapeutics, Inc. announced that it intends to offer for sale shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.

• miRagen Therapeutics Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia/lymphoma Patients With Residual Disease

  1/30/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced new efficacy and safety data from the ATLL arm of its ongoing Phase 1 clinical trial of cobomarsen, which will be presented at the 12th Annual T-Cell Lymphoma Forum in La Jolla, CA,